Effect of Cupping Therapy on Nitric Oxide Level in Patients With Cervical Spondylosis (CT)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with (cervical spondylosis) from both sexes.
- Age range (24-60) in chronic stages.
- BMI from20-25 kg/m2.
Exclusion Criteria:
- Renal and hepatic patients.
- Anemia, hepatic disease, and dermatological diseases.
- Morbid obese patients if their BMI exceeds the 25 kg/m2 will be also excluded.
- the patients are taking any medications known to affect the pain level
- The patients have a systemic illness, dermatological problems, skin allergy, local ischemic problems
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: cupping therapy
patients with cervical spondylosis will receive cupping therapy one time per month for three months
|
All the patients will be asked to be in a sitting position with both feet flat on the floor the cupping group will receive the cupping bloodletting at three acupuncture points (SI15, GB21, LI15) the medium size glass with a diameter of 4cm and a volume of 260ml. Each wet cupping treatment procedure will last about 20 min and will be conducted in five steps.
5 -Dressing |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the nitric oxide level
Time Frame: up to three months
|
Spectrophotometer device will be used to measure the level of nitric oxide
|
up to three months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
cervical range of motion
Time Frame: up to three months
|
electrogoniomter device will be used to assess cervical range of motion
|
up to three months
|
|
pain intensity
Time Frame: up to three months
|
visual analogue scale will be used to measure pain intensity.
The VAS is a 100-mm horizontal line that may be used to quantify symptoms in a continuous fashion.
It is easy to use and requires very little written language.
Patients are instructed to indicate the intensity of their pain by marking on a line anchored by "no pain" on the left and "worst imaginable pain" on the right.
|
up to three months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- P.T.REC/012/002532
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.